Literature DB >> 32666332

Dysregulated long non-coding RNAs involved in regulation of matrix degradation during type-B aortic dissection pathogenesis.

Hongjie Xu1, Boyao Zhang1, Yang Li1, Fan Yang1, Yang Liu1, Zhiyun Xu2, Guokun Wang3.   

Abstract

Thoracic aortic dissection (TAD) is a catastrophic disease with the rupture of aortic media resulted mainly from the degradation of extracellular matrix. With the deep study of long non-coding RNAs (lncRNAs) in cardiovascular diseases, the correlation between lncRNAs and the TAD pathogenesis is under revealed. In this study, we aimed to screen the differentially expressed lncRNAs involved in the regulation of matrix degradation during type-B aortic dissection (TBAD), whose pathogenesis is more similar to atherosclerosis. A total of 393 aberrantly expressed lncRNAs and 432 aberrantly expressed mRNAs were identified in the descending aortic samples from TBAD patients. Then, co-expression analysis was applied to analyze the correlation between the top five differentially expressed lncRNAs and aberrantly expressed mRNAs, so as to screen the lncRNAs involved in the regulation of matrix degradation. The results showed that two transcripts from lnc-TNFSF14 (lnc-TNFSF14-2, and lnc-TNFSF14-3) were negatively interacted with MMP14 and MMP19. Subsequently, quantitative real-time PCR assay confirmed that lnc-TNFSF14-2 were negatively correlated with MMP14 (rs = - 0.8180) and MMP19 (rs = - 0.8449), and lnc-TNFSF14-3 was also negatively correlated with MMP14 (rs = - 0.7098) and MMP19 (rs = - 0.7728) in descending aorta from TBAD patients (n = 20). Overall, our study found the aberrant lncRNAs expression profiles in TBAD, and identified lnc-TNFSF14 as a potential target regulating matrix degradation. The results also provided crucial clues for lncRNAs function research on TBAD development.

Entities:  

Keywords:  Co-expression network; Long non-coding RNAs; Matrix degradation; Type-B aortic dissection

Mesh:

Substances:

Year:  2020        PMID: 32666332     DOI: 10.1007/s11748-020-01441-z

Source DB:  PubMed          Journal:  Gen Thorac Cardiovasc Surg        ISSN: 1863-6705


  5 in total

Review 1.  Plasmin and matrix metalloproteinases in vascular remodeling.

Authors:  H R Lijnen
Journal:  Thromb Haemost       Date:  2001-07       Impact factor: 5.249

2.  HSP90 inhibitor 17-DMAG effectively alleviated the progress of thoracic aortic dissection by suppressing smooth muscle cell phenotypic switch.

Authors:  Zhimin Zhao; Yang Wang; Songhua Li; Suxuan Liu; Yang Liu; Yongchao Yu; Fan Yang; Zhiyun Xu; Guokun Wang
Journal:  Am J Transl Res       Date:  2019-01-15       Impact factor: 4.060

3.  Association of Matrix Metalloproteinase-2 and Matrix Metalloproteinase-9 With Endothelial Dysfunction, Cardiovascular Disease Risk Factors and thrombotic events in Children With End-stage Renal Disease.

Authors:  Alaleh Gheissari; Rokhsareh Meamar; Amin Abedini; Peyman Roomizadeh; Mohammad Shafiei; Zahra Samaninobandegani; Zhale Tabrizi; Farhad Mahmoudi; Alireza Merrikhi; Esfandiar Najafi Tavana
Journal:  Iran J Kidney Dis       Date:  2018-05       Impact factor: 0.892

4.  LncRNA and mRNA interaction study based on transcriptome profiles reveals potential core genes in the pathogenesis of human thoracic aortic dissection.

Authors:  Yang Li; Nan Yang; Xianbao Zhou; Xuezhi Bian; Genqiang Qiu; Mo Zhang; Huagang Lin; Dingfeng Li
Journal:  Mol Med Rep       Date:  2018-07-23       Impact factor: 2.952

Review 5.  Matrix metalloproteinases: inflammatory regulators of cell behaviors in vascular formation and remodeling.

Authors:  Qishan Chen; Min Jin; Feng Yang; Jianhua Zhu; Qingzhong Xiao; Li Zhang
Journal:  Mediators Inflamm       Date:  2013-06-12       Impact factor: 4.711

  5 in total
  1 in total

1.  Identification of Novel Long Noncoding RNAs and Their Role in Abdominal Aortic Aneurysm.

Authors:  Abulaihaiti Maitiseyiti; Hongbo Ci; Qingbo Fang; Sheng Guan; Alimujiang Shawuti; Huguo Wang; Xiaohu Ge
Journal:  Biomed Res Int       Date:  2020-12-21       Impact factor: 3.411

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.